EDGEWISE THERAPEUTICS ($EWTX) posted quarterly earnings results on Thursday, August 7th. The company reported earnings of -$0.34 per share, beating estimates of -$0.42 by $0.08. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $EWTX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
EDGEWISE THERAPEUTICS Insider Trading Activity
EDGEWISE THERAPEUTICS insiders have traded $EWTX stock on the open market 14 times in the past 6 months. Of those trades, 4 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $EWTX stock by insiders over the last 6 months:
- ADVISORS LLC ORBIMED has made 2 purchases buying 496,771 shares for an estimated $10,000,000 and 0 sales.
- PETER A. THOMPSON has made 2 purchases buying 496,771 shares for an estimated $10,000,000 and 0 sales.
- KEVIN KOCH (President and CEO) has made 0 purchases and 3 sales selling 5,276 shares for an estimated $101,376.
- JOANNE M. DONOVAN (CMO) sold 5,187 shares for an estimated $85,347
- ALAN J RUSSELL (Chief Scientific Officer) has made 0 purchases and 3 sales selling 2,951 shares for an estimated $67,677.
- JOHN R MOORE (General Counsel) sold 1,930 shares for an estimated $31,756
- BEHRAD DERAKHSHAN (Chief Business Officer) sold 1,691 shares for an estimated $27,824
- R MICHAEL CARRUTHERS (Chief Financial Officer) sold 1,314 shares for an estimated $21,620
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
EDGEWISE THERAPEUTICS Hedge Fund Activity
We have seen 92 institutional investors add shares of EDGEWISE THERAPEUTICS stock to their portfolio, and 103 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PERCEPTIVE ADVISORS LLC added 3,861,791 shares (+143.8%) to their portfolio in Q1 2025, for an estimated $84,959,402
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 1,271,245 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $27,967,390
- FIRST LIGHT ASSET MANAGEMENT, LLC added 1,071,651 shares (+137.3%) to their portfolio in Q1 2025, for an estimated $23,576,322
- SIREN, L.L.C. added 962,101 shares (+131.0%) to their portfolio in Q1 2025, for an estimated $21,166,222
- VIKING GLOBAL INVESTORS LP removed 734,951 shares (-60.0%) from their portfolio in Q1 2025, for an estimated $16,168,922
- CORMORANT ASSET MANAGEMENT, LP added 695,458 shares (+20.4%) to their portfolio in Q1 2025, for an estimated $15,300,076
- DEEP TRACK CAPITAL, LP added 689,579 shares (+97.1%) to their portfolio in Q1 2025, for an estimated $15,170,738
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
EDGEWISE THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $EWTX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 06/30/2025
- RBC Capital issued a "Outperform" rating on 06/05/2025
- Wedbush issued a "Outperform" rating on 04/21/2025
- Piper Sandler issued a "Overweight" rating on 04/02/2025
To track analyst ratings and price targets for EDGEWISE THERAPEUTICS, check out Quiver Quantitative's $EWTX forecast page.
EDGEWISE THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $EWTX recently. We have seen 5 analysts offer price targets for $EWTX in the last 6 months, with a median target of $43.0.
Here are some recent targets:
- Joseph Pantginis from HC Wainwright & Co. set a target price of $42.0 on 06/30/2025
- Leonid Timashev from RBC Capital set a target price of $48.0 on 06/05/2025
- Laura Chico from Wedbush set a target price of $43.0 on 04/21/2025
- Louise Chen from Scotiabank set a target price of $14.0 on 04/03/2025
- Yasmeen Rahimi from Piper Sandler set a target price of $51.0 on 04/02/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
